Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
  • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/06—Antiasthmatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/14—Antivirals for RNA viruses
  • A61P31/18—Antivirals for RNA viruses for HIV
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P39/00—General protective or antinoxious agents
  • A61P39/06—Free radical scavengers or antioxidants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

• the present invention relates, in general, to a method of modulating physiological and pathological processes and, in particular, to a method of modulating cellular levels of oxidants and thereby processes in which such oxidants are a participant.
• the invention also relates to compounds and compositions suitable for use in such methods.
• Oxidants are produced as part of the normal metabolism of all cells but also are an important component of the pathogenesis of many disease processes.
• Reactive oxygen species for example, are critical elements of the pathogenesis of diseases of the lung, the central nervous system and skeletal muscle.
• Oxygen free radicals also play a role in modulating the effects of nitric oxide (NO-)- In this context, they contribute to the pathogenesis of vascular disorders, inflammatory diseases and the aging process.
• NO- nitric oxide
• SODs superoxide dismutases
• O2 into H2O2 plus O2, and represent the first line of defense against the detrimental effects of superoxide radicals.
• Mammals produce three distinct SODs. One is a dimeric copper- and zinc-containing enzyme (CuZn SOD) found in the cytosol of all cells. A second is a tetrameric manganese-containing SOD (Mn SOD) found within mitochondria, and the third is a tetrameric, glycosylated, copper- and zinc -containing enzyme (EC-SOD) found in the extracellular fluids and bound to O 99/55388
• CuZn SOD dimeric copper- and zinc-containing enzyme
• Mn SOD tetrameric manganese-containing SOD
• EC-SOD tetrameric, glycosylated, copper- and zinc -containing enzyme
• antioxidant enzymes are known to exist within cells, including catalase and glutathione peroxidase. While extracellular fluids and the extracellular matrix contain only small amounts of these enzymes, other extracellular antioxidants are also known to be present, including radical scavengers and inhibitors of lipid peroxidation, such as ascorbic acid, uric acid, and ⁇ -tocopherol (Halliwell et al, Arch. Biochem. Biophys. 280:1 (1990)).
• the present invention relates generally to low molecular weight porphyrin compounds suitable for use in modulating intra- and extracellular processes in which superoxide radicals, or other oxidants such as hydrogen peroxide or peroxynitrite, are a participant.
• the compounds and methods of the invention find application in various physiologic and pathologic processes in which oxidative stress plays a role.
• the present invention relates to a method of modulating intra- or extracellular levels of oxidants such as superoxide radicals, hydrogen peroxide, peroxynitrite, lipid peroxides, hydroxyl radicals and thiyl radicals. More particularly, the invention relates to a method of modulating normal or pathological processes involving superoxide radicals, hydrogen peroxide, nitric oxide or peroxynitrite using low molecular weight antioxidants, and to methine (ie, meso) substituted porphyrins suitable for use in such a method.
• oxidants such as superoxide radicals, hydrogen peroxide, peroxynitrite, lipid peroxides, hydroxyl radicals and thiyl radicals. More particularly, the invention relates to a method of modulating normal or pathological processes involving superoxide radicals, hydrogen peroxide, nitric oxide or peroxynitrite using low molecular weight antioxidants, and to methine (ie, meso) substituted por
• FIG. 1 shows the structures of certain compounds of the invention.
• the SOD activity values were determined using the method of McCord and Fridovich, J. Biol. Chem. 244:6049 (1969).
• the TBARS values were obtained as follows:
• Frozen adult Sprague-Dawley rat brains, livers and mouse lungs were homogenized with a polytron (Turrax T25, Germany) in 5 volumes of ice cold 50 mM potassium phosphate at pH 7.4. Homogenate protein concentration was determined with the Coomassie Plus protein assay (Pierce, Rockford, IL) using bovine serum albumin as a standard. The homogenate volume was adjusted with buffer to give a final protein concentration of lOmg/ml and frozen as aliquots at -80°C.
• Microfuge tubes 1.5 ml containing 0.2 ml of homogenate (0.2 mg protein) and various concentrations of antioxidant were incubated at 37°C for 15 minutes.
• Oxidation of the rat brain homogenate was initiated by the addition of 0.1 ml of a freshly prepared stock anaerobic solution containing ferrous chloride (0.25 mM) and ascorbate (1 mM). Samples were placed in a shaking water bath at 37°C for 30 minutes (final volume 1 ml). The reactions were stopped by the addition of 0.1 ⁇ L of a stock butylated hydroxytoluene (60 mM) solution in ethanol.
• TBARS tbiobarbituric acid reactive species
• the present invention relates to methods of protecting against the deleterious effects of oxidants, particularly, superoxide radicals, hydrogen peroxide and peroxynitrite, and to methods of preventing and treating diseases and disorders that involve or result from oxidant stress.
• the invention also relates methods of modulating biological processes involving oxidants, including superoxide radicals, hydrogen peroxide, nitric oxide and peroxynitrite.
• the invention further relates to compounds and compositions, including low molecular weight antioxidants (eg mimetics of scavengers of reactive oxygen species, including mimetics of SODs, 99/55388
• catalases and peroxidases and formulations thereof, suitable for use in such methods.
• Mimetics of scavengers of reactive oxygen species appropriate for use in the present methods include methine (ie meso) substituted porphines, or pharmaceutically acceptable salts thereof (eg chloride or bromide salts).
• the invention includes both metal-free and metal-bound porphines.
• metal-bound porphines manganic derivatives of methine (meso) substituted porphines are preferred, however, metals other than manganese such as iron (II or III), copper (I or II), cobalt (II or III), or nickel (I or II), can also be used.
• the metal selected can have various valence states, for example, manganese II, III or V can be used. Zn (II) can also be used even though it does not undergo a valence change and therefore will not directly scavenge superoxide.
• the choice of the metal can affect selectivity of the oxygen species that is scavenged.
• Iron-bound porphines for example, can be used to scavenge NO- while manganese- bound porphines scavenge less well.
• the mimetics of the present invention are of the Formula I:
• R, and R 3 are, independently:
• R 2 is:
• R 4 is:
• R, and R 3 are, independently, -CO 2 C,. 3 alkyl
• R, or R 3 is -CO 2 CH 3 , -CO 2 CH 2 CH 3 , or -CON(CH 3 ) 2
• Rtent R 2 and R 3 are, independently, -CO 2 CH 3 or -CO 2 CH 2 CH 3
• R 4 is -H, -COOH, -CO 2 CH 3 or -CO 2 CH 2 CH 3 or -CO 2 CH 2 CH 3 .
• R réelle R 2 , R 3 and R 4 are, independently, -CO 2 CH 3 or -CO 2 CH 2 CH 3 .
• one or more of the py ⁇ ole rings of the porphyrin of Formula I can be substituted at any or all beta carbons, ie: 2, 3, 7, 8, 12, 13, 17 or 18.
• substituents, designated P can be hydrogen or an electron withdrawing group, for example, each P can, independently, be a NO 2 group, a halogen (eg Cl, Br or F), a nitrile group, a vinyl group, or a formyl group.
• substituents alter the redox potential of the porphyrin and thus enhance its ability to scavenge oxygen radicals.
• halogen eg Br
• substituents preferably, 1-4
• the remaining P's advantageously being hydrogen.
• P formyl
• P NO 2
• Mimetics preferred for use in the present methods can be selected by assaying for SOD, catalase and/or peroxidase activity. Mimetics can also be screened for their ability to inhibit lipid peroxidation. 99/55388
• SOD activity can be monitored in the presence and absence of EDTA using the method of McCord and Fridovich (J. Biol. Chem. 244:6049 (1969)).
• the efficacy of a mimetic can also be determined by measuring the effect of the mimetic on the aerobic growth of a SOD null E. coli strain versus a parent strain.
• parental E. coli (ABl 157) and SOD null E. coli. JI132
• M9 medium containing 0.2% casamino acids and 0.2% glucose at pH 7.0 and 37°C
• growth can be monitored in terms of turbidity followed at 700 nm.
• This assay can be made more selective for SOD mimetics by omitting the branched chain, aromatic and sulphur-containing amino acids from the medium (glucose minimal medium (M9), plus 5 essential amino acids).
• Efficacy of active mimetics can also be assessed by determining their ability to protect mammalian cells against methylviologen (paraquat)-induced toxicity. Specifically, rat L2 cells grown as described below and seeded into 24 well dishes can be pre-incubated with various concentrations of the SOD mimetic and then incubated with a concentration of methylviologen previously shown to produce an LC75 in control L2 cells. Efficacy of the mimetic can be co ⁇ elated with a decrease in the methylviologen-induced LDH release (St. Clair et al, FEBS Lett. 293:199 (1991)).
• mice can be randomized into 4 groups of 8 mice each to form a standard 2X2 contingency statistical model. Animals can be treated with either paraquat (40 mg/kg, ip) or saline and treated with SOD mimetic or vehicle control. Lung injury can be assessed 48 hours after paraquat treatment by analysis of bronchoalveolar Iavage fluid (BALF) damage parameters (LDH, protein and % PMN) as previously described (Hampson et al, Tox. Appl. Pharm. 98:206 (1989); Day et al, J. Pharm. Methods 24:1 (1990)). Lungs from 2 mice of each group can 99/55388
• Catalase activity can be monitored by measuring absorbance at 240nm in the presence of hydrogen peroxide (see Beers and Sizer, J. Biol. Chem. 195:133 (1952)) or by measuring oxygen evolution with a Clark oxygen electrode (Del Rio et al, Anal. Biochem. 80:409 (1977)).
• Peroxidase activity can be measured spectrophotometrically as previously described by Putter and Becker: Peroxidases. In: Methods of Enzymatic Analysis, H.U. Bergmeyer (ed.), Verlag Chemie, Weinheim, pp. 286-292 (1983). Aconitase activity can be measured as described by Gardner and Fridovich (J. Biol. Chem. 266:19328 (1991)). The selective, reversible and SOD-sensitive inactivation of aconitase by known O " 2 generators can be used as a marker of intracellular O " 2 generation. Thus, suitable mimetics can be selected by assaying for the ability to protect aconitase activity.
• Active mimetics can be tested for toxicity in mammalian cell culture by measuring lactate dehydrogenase (LDH) release.
• LDH lactate dehydrogenase
• rat L2 cells a lung Type II like cell (Kaighn and Douglas, J. Cell Biol. 59:160a (1973)
• cells can be seeded at equal densities in 24 well culture dishes and grown to approximately 90% confluence
• SOD mimetics can be added to the cells at log doses (eg micromolar doses in minimal essential medium (MEM)) and incubated for 24 hours.
• MEM minimal essential medium
• Toxicity can be assessed by morphology and by measuring the release of the cytosolic injury marker, LDH (eg on a thermokinetic plate reader), as described by Vassault (In: Methods of Enzymatic Analysis, Bergmeyer (ed) pp. 118-26 (1983); oxidation of NADH is measured at 340 nm).
• LDH cytosolic injury marker
• Synthesis of various mimetics suitable for use in the present method can be effected using art-recognized protocols (see, for example Sastry et al, Anal. Chem. 41:857 (1969), Pasternack et al, Biochem. 22:2406 (1983); Richards et al, Inorg. Chem. 35: 1940 (1996) and U.S. Appln. No. 08/663,028, particularly the details therein relating to syntheses). Synthesis of a number of mimetics of the invention are set forth in the Examples that follow.
• the mimetics of the present invention are suitable for use in a variety of methods.
• the compounds of Formula I particularly the metal bound forms (advantageously, the manganese bound forms), are characterized by the ability to inhibit lipid peroxidation. Accordingly, these compounds are prefe ⁇ ed for use in the treatment of diseases or disorders associated with elevated levels of lipid peroxidation. The compounds are further prefe ⁇ ed for use in the treatment of diseases or disorders mediated by oxidative stress. Inflammation diseases are an example.
• the compounds of the invention can also be used in methods designed to regulate NO- levels by targeting the above-described porphines to strategic locations.
• NO- is an intercellular signal and, as such, NO- must traverse the extracellular matrix to exert its effects.
• NO- is highly sensitive to inactivation mediated by O 2 " present in the extracellular spaces.
• the methine (meso) substituted porphyrins of the invention can increase bioavalability of NO' by preventing its degradation by O 2 " .
• the present invention relates, in a further specific embodiment, to a method of inhibiting production of superoxide radicals.
• the mimetics of the invention are used to inhibit oxidases, such as xanthine oxidase, that are responsible for production of superoxide radicals.
• oxidases such as xanthine oxidase
• xanthine/xanthine oxidase-induced injury can be assessed, for example, by growing rat L2 cells in 24-weII dishes. Cells can be pre-incubated with various concentrations of a mimetic and then xanthine oxidase (XO) can be added to the culture along with xanthine (X). The appropriate amount of XO/X used in the study can be pre-determined for each cell line by performing a dose-response curve for injury. X/XO can be used in an amount that produces approximately an LC75 in the culture. Efficacy of the mimetic can be co ⁇ elated with a decrease in XO/X- induced LDH release.
• the mimetics of the invention can also be used as catalytic scavengers of reactive oxygen species to protect against ischemia reperfusion injuries associated with myocardial infarction, stroke, acute head trauma, organ reperfusion following transplantation, bowel ischemia, hemo ⁇ hagic stock, pulmonary infarction, surgical occlusion of blood flow, and soft tissue injury.
• the mimetics can further be used to protect against skeletal muscle reperfusion injuries.
• the mimetics (particularly, metal bound forms) can also be used to protect against damage to the eye due to sunlight (and to the skin) as well as glaucoma, and macular degeneration of the eye.
• the mimetics of the invention can also be used as catalytic scavengers of reactive oxygen species to increase the very limited storage viability of transplanted hearts, kidneys, skin and other organs and tissues.
• the invention also provides methods of inhibiting damage due to autoxidation of substances resulting in the formation of O 2 ' including food products, pharmaceuticals, stored blood, etc.
• the mimetics of the invention are added to food products, pharmaceuticals, stored blood and the like, in an amount sufficient to inhibit or prevent oxidation damage and thereby to inhibit or prevent the degradation associated with the autoxidation reactions. (For other uses of the mimetics of the invention, see USP 5,227,405).
• the amount of mimetic to be used in a particular treatment or to be associated with a particular substance can be determined by one skilled in the art.
• the mimetics (particularly, metal bound forms) of the invention can further be used to scavenge hydrogen peroxide and thus protect against formation of the highly reactive hydroxyl radical by interfering with Fenton chemistry (Aruoma and Halliwell, Biochem. J. 241:273 (1987); Mello Filho et al, Biochem. J. 218:273 (1984); Rush and Bielski, J. Phys. Chem. 89:5062 (1985)).
• the mimetics (particularly, metal bound forms) of the invention can also be used to scavenge peroxynitrite, as demonstrated indirectly by inhibition of the oxidation of dihydrorhodamine 123 to rhodamine 123 and directly by accelerating peroxynitrite degradation by stop flow analysis.
• diseases/disorders appropriate for treatment using the mimetics of the present invention include diseases of the central nervous system (including AIDS dementia, stroke, amyotrophic lateral sclerosis (ALS), Parkinson's disease and Huntington's disease) and diseases of the musculature (including diaphramic diseases (eg respiratory fatigue in emphysema, bronchitis and cystic fibrosis), cardiac fatigue of congestive heart failure, muscle weakness syndromes associated with myopathies, ALS and multiple sclerosis).
• diseases of the central nervous system including AIDS dementia, stroke, amyotrophic lateral sclerosis (ALS), Parkinson's disease and Huntington's disease
• diseases of the musculature including diaphramic diseases (eg respiratory fatigue in emphysema, bronchitis and cystic fibrosis), cardiac fatigue of congestive heart failure, muscle weakness syndromes associated with myopathies, ALS and multiple sclerosis).
• NMD A glutamate receptor
• NO- oxygen free radicals
• NMDA-toxicity Well-established neuronal cortical culture models of NMDA-toxicity have been developed and used as the basis for drug development. In these same systems, the mimetics of the present invention inhibit NMDA induced injury.
• O * 2 radicals are an obligate step in the intracellular events culminating in excitotoxic death of cortical neurons and further demonstrate that the mimetics of the invention can be used to scavenge O ' 2 radicals and thereby serve as protectants against excitotoxic injury.
• the present invention also relates to methods of treating AIDS.
• the Nf Kappa B promoter is used by the HIV virus for replication. This promoter is used by the HIV virus for replication. This promoter is redox sensitive, therefore, an oxidant can regulate this process. This has been shown previously for two metalloporphyrins distinct from those of the present invention (Song et al, Antiviral Chem. and Chemother. 8:85 (1997)).
• the invention also relates to methods of treating arthritis, systemic hypertension, atherosclerosis, edema, septic shock, pulmonary hypertension, including primary pulmonary hypertension, impotence, infertility, endometriosis, premature uterine contractions, microbial infections, gout and in the treatment of Type II diabetes mellitus.
• the mimetics of the invention can be used to ameliorate the toxic effects associated with endotoxin, for example, by preserving vascular tone and preventing multi-organ system damage.
• inflammations are amenable to treatment using the present mimetics (particularly, metal bound forms) (note particularly the inflammatory based disorders of asthma, ARDS including oxygen toxicity, pneumonia (especially AIDS-related pneumonia), cystic fibrosis, chronic sinusitis and autoimmune diseases (such as rheumatoid arthritis)).
• EC-SOD is localized in the interstitial spaces su ⁇ ounding airways and vasculature smooth muscle cells.
• EC-SOD and O 2 mediate the antiinflammatory - proinflammatory balance in the alveolar septum. NO- released by alveolar septal cells acts to suppress inflammation unless it reacts with O 2 " to form ONOO".
• EC-SOD tips the balance in the alveolar septum against inflammation. Significant amounts of ONOO" will form only when EC-SOD is deficient or when there is greatly increased O 2 ' release. Mimetics described herein can be used to protect against destruction caused by hyperoxia.
• the invention further relates to methods of treating memory disorders. It is believed that nitric oxide is a neurotransmitter involved in long-term memory potentiation. Using an EC-SOD knocked-out mouse model (Carlsson et al, Proc. Natl. Acad. Sci. USA 92:6264 (1995)), it can be shown that learning impairment co ⁇ elates with reduced superoxide scavenging in extracellular spaces of the brain. Reduced scavenging results in higher extracellular O " 2 levels. O " 2 is believed to react with nitric oxide thereby preventing or inhibiting nitric oxide-mediated neuro transmission and thus long-term memory potentiation.
• the mimetics of the invention particularly, metal bound forms, can be used to treat dementias and memory/learning disorders.
• compositions suitable for use in the present methods can be formulated into pharmaceutical compositions suitable for use in the present methods.
• Such compositions include the active agent (mimetic) together with a pharmaceutically acceptable carrier, excipient or diluent.
• the composition can be present in dosage unit form for example, tablets, capsules or suppositories.
• the composition can also be in the form of a sterile solution suitable for injection or nebulization.
• Compositions can also be in a form suitable for opthalmic use.
• the invention also includes compositions formulated for topical administration, such compositions taking the form, for example, of a lotion, cream, gel or ointment.
• the concentration of active agent to be included in the composition can be selected based on the nature of the agent, the dosage regimen and the result sought.
• the dosage of the composition of the invention to be administered can be determined without undue experimentation and will be dependent upon various factors including the nature of the active agent (including whether metal bound or metal free), the route of administration, the patient, and the result sought to be achieved.
• a suitable dosage of mimetic to be administered IV or topically can be expected to be in the range of about 0.01 to 50 mg/kg day, preferably, 0.1 to 10 mg/kg/day.
• For aerosol administration it is expected that doses will be in the range of 0.001 to 5.0 mg/kg/day, preferably, 0.01 to 1 mg/kg/day. Suitable doses of mimetics will vary, for example, with the mimetic and with the result sought.
• reaction mixture was heated at 145 °C for 1-1.5 h then exposed to a stream of air.
• the reaction mixture was
• Porphyrins 4 and 5 were also isolated during the chromatographic purification of the
• Celite provided, after evaporation of solvents, a crude solid mixture which was adsorbed
• reaction mixture was heated at 145 °C for 1-1.5 h then exposed to a stream of air.
• the reaction mixture was
• Porphyrin 10 was also isolated by chromatography from the metalation process above:
• reaction mixture was stirred overnight at room temperature. The reaction mixture was
• porphyrin 15 (117 mg): mp >300 °C; UV-
• silica gel (3 g) and was purified by column chromatography (gradient elution with
• porphyrin 20 porphyrin 30 (10 mg, 1.2%) and porphyrin 31 (30 mg, 2.9%):
• porphyrin 30 l H NMR (300 MHz, CDC1 3 ) ⁇ -3.62 (s, 2 H), 1.31 (t, 3 H), 2.24 (m, 2 H),
• reaction solution was decanted, dried (Na 2 SO 4 ), filtered and the solvent removed in
• porphyrin 36 (36 mg, 0.043 mmol), MnC (27 mg, 0.21 mmol) and DMF (10 ml).
• reaction mixture was heated to 140 °C for 2 h, then exposed to a stream of air. After 5 h,
• porphyrin 40 50- 100% CH j Cl j /hexanes afforded porphyrin 40 (0.36 g; 11%) as a dark violet solid:
• reaction mixture was cooled to room temperature
• porphyrin 20 porphyrin 51 (38 mg) and porphyrin 52 (54 mg).
• porphyrin 51 'H
• reaction mixture was heated at 145 °C for 1 h then exposed to a stream of air.
• the reaction mixture was
• reaction mixture was heated at 145 °C for 1.5 h then exposed to a stream of air.
• the reaction mixture was
• Porphyrin 68 ⁇ NMR
• MeOH/OLCy provided compound 70 (25 mg; 34%) as a dark solid: mp >300 °C; UV-
• Porphyrin 77 ⁇ NMR (300 MHz, CDC1 3 ) ⁇ -3.41 (s, 2 H), 1.11 (t, 6 H), 1.69 (m, 4 H),
• Porphyrin 78 'H NMR (300 MHz, CDC1 3 ) ⁇ -3.34 (s, 2 H), 1.11 (7, 9 H), 1.70 (m, 6 H), 2.13 (m, 6 H), 4.60 (s, 3 H),
• reaction mixture was heated at 145 °C for 2 h. The reaction mixture was then exposed to a stream of air as
• Porphyrins 80 (10 mg), and 81 (1 mg).
• reaction mixture The reaction mixture was exposed to a stream of air and heating was
• Trifluoroacetic acid (3.8 mL, 0.049 mol) was then added. The resulting dark solution was
• dipyrromethane 47 150 mg, 0.687
• Pulmonary toxicity due to hyperoxia is thought to be related to the formation of reactive oxygen species, including superoxide.
• Increased levels of antioxidant enzymes such as superoxide dismutases (SOD) and catalase, have been associated with increased survival and adaptation to hyperoxia in rats and mice.
• SOD superoxide dismutases
• catalase catalytic antioxidant in conferring protection from hyperoxic lung injury to rats was examined.
• the compound is a manganic porphyrin (AEOL- 11201 (see Fig. 1)) with a broad spectrum of antioxidant properties.
• Male Sprague- Dawley rats were exposed to 100% O 2 , 635 mrnHG, for 7 days. The animals were injected with the compound at 15 mg/kg, or the vehicle intraperitoneally every 24 hours.
• Perivascular edema a marker of hyperoxic lung injury, was evaluated on hematoxylin and eosin stained lung sections. Compared to the air control animals, the oxygen exposed group developed significant perivascular edema. AEOL-11201 significantly reduced the edema of small to medium sized vessels in O 2 exposed rats. These results indicate that manganic porphyrins are useful as therapeutic antioxidants in disease states in which reactive oxygen species are involved.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Pulmonology (AREA)
• Virology (AREA)
• AIDS & HIV (AREA)
• Tropical Medicine & Parasitology (AREA)
• Molecular Biology (AREA)
• Toxicology (AREA)
• Communicable Diseases (AREA)
• Oncology (AREA)
• Biomedical Technology (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Biochemistry (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)

Priority Applications (6)

Applications Claiming Priority (2)

Publications (2)

Family

ID=22174053

Family Applications (1)

Country Status (10)

Cited By (12)

Families Citing this family (20)

Citations (2)

Family Cites Families (56)

• 1999
  • 1999-04-23 AU AU37588/99A patent/AU771259B2/en not_active Ceased
  • 1999-04-23 AT AT99919995T patent/ATE311206T1/de not_active IP Right Cessation
  • 1999-04-23 WO PCT/US1999/008905 patent/WO1999055388A1/en not_active Ceased
  • 1999-04-23 CA CA2329751A patent/CA2329751C/en not_active Expired - Fee Related
  • 1999-04-23 EP EP99919995A patent/EP1071474B1/en not_active Expired - Lifetime
  • 1999-04-23 US US09/296,615 patent/US6479477B1/en not_active Expired - Lifetime
  • 1999-04-23 DK DK99919995T patent/DK1071474T3/da active
  • 1999-04-23 JP JP2000545584A patent/JP4648542B2/ja not_active Expired - Fee Related
  • 1999-04-23 ES ES99919995T patent/ES2257858T3/es not_active Expired - Lifetime
  • 1999-04-23 DE DE69928655T patent/DE69928655T2/de not_active Expired - Lifetime

Patent Citations (2)

Also Published As

Similar Documents

Legal Events